FDA Approves Daklinza (daclatasvir) for the Treatment of Patients with Gen. 3
Tig said
Aug 6, 2015
Hey Nirmalee,
I love your upbeat message! We need to hear these kinds of positive and informative posts. It really makes an important statement for those coming behind us. I'm thrilled to hear you're improving so well! Keep it up
dragonfly said
Aug 6, 2015
This is the best chance for geno 3s. I had failed 2 lots of other treatment and on this I was clear within 2 weeks! I am so happy that this opportunity is available to others now. If you get offered it - take it and it will change your life. I have lived with increasingly debilitating symptomns for a very long time and now they are gone. I no longer have that awful pressure in my ribcage or referred pain in my shoulder. My illness no longer dictates my life.
Best wishes,
Nirmalee
Groupergetter said
Aug 5, 2015
Jill, I had overlooked this newly approved treatment for the US market. Folks with genotype 3 may find it interesting. Thanks for sharing
Cinnamon Girl said
Jul 28, 2015
Bristol-Myers Squibb Company announced today (24 July, 2015) that Daklinza (daclatasvir), an NS5A replication complex inhibitor, has been approved by the U.S. Food and Drug Administration (FDA).
This approval marks the first time patients with chronic hepatitis C virus (HCV) genotype 3 have a 12-week, once-daily, all-oral treatment option. Daklinza is indicated for use with sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection.
Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving this regimen. The recommended dosage of Daklinza is 60 mg in combination with sofosbuvir for 12 weeks.
Hey Nirmalee,
I love your upbeat message! We need to hear these kinds of positive and informative posts. It really makes an important statement for those coming behind us. I'm thrilled to hear you're improving so well! Keep it up
This is the best chance for geno 3s. I had failed 2 lots of other treatment and on this I was clear within 2 weeks! I am so happy that this opportunity is available to others now. If you get offered it - take it and it will change your life. I have lived with increasingly debilitating symptomns for a very long time and now they are gone. I no longer have that awful pressure in my ribcage or referred pain in my shoulder. My illness no longer dictates my life.
Best wishes,
Nirmalee
Jill, I had overlooked this newly approved treatment for the US market. Folks with genotype 3 may find it interesting. Thanks for sharing
Bristol-Myers Squibb Company announced today (24 July, 2015) that Daklinza (daclatasvir), an NS5A replication complex inhibitor, has been approved by the U.S. Food and Drug Administration (FDA).
This approval marks the first time patients with chronic hepatitis C virus (HCV) genotype 3 have a 12-week, once-daily, all-oral treatment option. Daklinza is indicated for use with sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection.
Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving this regimen. The recommended dosage of Daklinza is 60 mg in combination with sofosbuvir for 12 weeks.
Link to full details of press release...
http://www.businesswire.com/news/home/20150724005696/en/FDA-Approves-Daklinza-daclatasvir-Treatment-Patients-Chronic#.VbeoR7Zkih9